Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Redx Pharma Agrees Dishman Collaboration

Published: Tuesday, September 25, 2012
Last Updated: Tuesday, September 25, 2012
Bookmark and Share
License agreement will allow Dishman to use process technology patented by the Liverpool-based firm.

The early stage drug development company Redx Pharma has announced a license agreement that will allow Dishman Pharmaceuticals & Chemicals to use process technology patented by the Liverpool-based firm.

The deal will see Dishman, which is listed on the Mumbai stock exchange and is a global supplier to the pharmaceutical industry, employ the Redx technology for the synthesis of statins, one of the world’s best selling classes of prescription drugs.

Financial terms were not disclosed but it is anticipated that the deal will generate multi-million dollar revenues for both companies.

Dr Neil Murray, chief executive of Redx Pharma, commented: “This collaboration will create substantial revenues from our intellectual property portfolio and is the first of many deals we look forward to announcing. We are delighted to work with Dishman and pleased to have reached this agreement.”

“We are delighted to be able to offer our customers access to Redx Pharma’s technology and thus create opportunities for the pharmaceutical companies we serve.” commented Christian Dowdeswell, Commercial Director Dishman Group.

Dowdeswell continued, “This deal fits very neatly into Dishman Group’s core principle of investment and innovation and ensures that we can continue to offer high value, high quality products to our customers into the future.”

Redx Pharma is developing a portfolio of new drug candidates across multiple therapeutic areas. These new medicines offer patient benefits that include greater efficacy and fewer side effects.

The drug development programmes are characterized by demonstrably lower risk and greater speed into development - and create licensing opportunities for large pharma companies.

Earlier this year Redx launched its first spin out business, Redx Oncology, and is presently planning a second, Redx Anti-Infectives.

As a global partner for pharmaceutical companies, Dishman has a portfolio of products and development, scale-up and manufacturing services.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pioneering Cancer Research Firm Opens in Liverpool
Launch of Redx Oncology, a new cancer research and development company based in Liverpool.
Tuesday, April 03, 2012
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos